Company / Cash & Equivalents
Enveric Biosciences, Inc. Cash & Equivalents History
FY2017-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$1.4M
FY2019
5-year range
$1.4M / $1.4M
FY2017-FY2019
Trend
+0.0%
vs FY2018
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents remained relatively stable over the past 3 years, with values between $1M and $1M.
Based on SEC 10-K filings.
$1M in FY2019.
Remained stable around $1M over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2019, cash & equivalents increased 0.0% year-over-year.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2019 | $1.4M | +0.0% |
| FY2018 | $1.4M | -0.6% |
| FY2017 | $1.4M | - |
As of FY2019 · SEC 10-K · Updated Jun 24, 2026